카지노 슬롯 머신

On July 24th, 카지노 슬롯 머신, an innovative new drug development specialist company utilizing Targeted Protein Degradation (TPD) technology, announced the successful acquisition of 10 billion won (.7 million) Series B bridge investment from Yuan Bio Venture Capital, a renowned Chinese bio-specialized venture capital firm.

Established in 2018, 카지노 슬롯 머신 aims to bring hope to patients previously difficult to treat and explore new possibilities for alleviating despair through TPD technology. The company has raised 2.6 billion won ( million) in the pre-series A round, 12.7 billion won (.8 million) in the series A round, and 28 billion won (.6 million) in the series B round. With this recent Series B bridge investment of 10 billion won (.7 million), 카지노 슬롯 머신's total cumulative investment now stands at 53 billion won (.8 million). Additionally, the company has signed contracts with Daishin Securities to prepare for an Initial Public Offering (IPO).

Yuan Bio Venture Capital, the sole participant in this bridge 카지노 슬롯 머신, was founded in 2013 and has emerged as one of China's top 10 bio-healthcare specialized 카지노 슬롯 머신 firms, focusing on early and growth-stage companies. To date, the firm has invested in approximately 170 companies, with 19 portfolio companies listed on the NASDAQ and Hong Kong Stock Exchange, and manages assets worth around 1.3 billion dollars.

카지노 슬롯 머신 attributes Yuan Bio's investment to high expectations for the global technology transfer potential of the TPD-based PLK1-degrading anti-cancer drug, the originality of the subsequent degrader new drug pipeline, and the scalability of the novel E3 ligase platform technology.

Currently, 카지노 슬롯 머신's anti-cancer drug pipeline, targeting PLK1 protein degradation, is receiving national drug development support and is undergoing non-clinical research to advance into clinical trials under the U.S. Food and Drug Administration (FDA). The follow-up pipeline, targeting AURKA protein degradation, has been selected as a national new drug development project this year.

In collaboration with Yuhan Corporation and Boryung Pharm, 카지노 슬롯 머신 is conducting joint R&D for the subsequent pipeline. The company is also researching the discovery of platform binders functioning on Novel E3 ligases, utilizing their self-developed technologies, 'UPPGRADERTM (selecting promising Novel E3 ligases with TPD access)' and 'UPPBEATTM (discovering new binders that function on selected E3 ligase)'.

CEO Si-Woo Choi commented, "The raised 카지노 슬롯 머신 will be allocated towards the clinical research of the PLK1 Degrader pipeline, optimization research for subsequent pipelines, and research on the Novel E3 ligase platform pipeline." He further stated, "In the short term, we aim to achieve commercialization success through global technology transfer of the PLK1 Degrader pipeline. In the long term, we will proactively invest in the development of Novel E3 ligase platform binders, which will become the core growth driver in the TPD industry. This strategic move will enable us to grow into a global specialized pharmaceutical company focused on TPD."